MTB-9655

MetaboMed Inc · Phase 1 active Small molecule

At a glance

Generic name	MTB-9655
Sponsor	MetaboMed Inc
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Study of MTB-9655, an Inhibitor of ACSS2, in Patients With Advanced Solid Tumors (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

MTB-9655 CI brief — competitive landscape report
MTB-9655 updates RSS · CI watch RSS
MetaboMed Inc portfolio CI